{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,22]],"date-time":"2026-04-22T14:36:26Z","timestamp":1776868586242,"version":"3.51.2"},"reference-count":23,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2026,3,31]],"date-time":"2026-03-31T00:00:00Z","timestamp":1774915200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2026,3,31]],"date-time":"2026-03-31T00:00:00Z","timestamp":1774915200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"name":"Shionogi Inc."}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Drug Investig"],"published-print":{"date-parts":[[2026,5]]},"DOI":"10.1007\/s40261-026-01541-3","type":"journal-article","created":{"date-parts":[[2026,3,31]],"date-time":"2026-03-31T10:47:02Z","timestamp":1774954022000},"page":"561-570","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Effects of Ensitrelvir on the Pharmacokinetics of Combined Oral Contraceptives (Ethinyl Estradiol\/Drospirenone) in Healthy Adult Women: A Phase 1 Fixed-Sequence, Multiple-Dose, Drug\u2013Drug Interaction Study"],"prefix":"10.1007","volume":"46","clinical-trial-number":[{"clinical-trial-number":"nct06775730","registry":"10.18810\/clinical-trials-gov"}],"author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9666-8678","authenticated-orcid":false,"given":"Ryosuke","family":"Shimizu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Risa Yokokawa","family":"Shibata","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ryuji","family":"Kubota","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sho","family":"Okuda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takuhiro","family":"Sonoyama","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,3,31]]},"reference":[{"key":"1541_CR1","unstructured":"World Health Organization. WHO COVID-19 dashboard: COVID-19 cases, World. https:\/\/data.who.int\/dashboards\/covid19\/cases. Accessed 18 July 2025."},{"key":"1541_CR2","doi-asserted-by":"publisher","first-page":"1401726","DOI":"10.3389\/fpubh.2025.1401726","volume":"13","author":"E Barfar","year":"2025","unstructured":"Barfar E, Raei B, Daneshi S, Bagher Barahouei F, Hushmandi K. The burden of COVID-19 based on disability-adjusted life years: a systematic review of available evidence. Front Public Health. 2025;13:1401726.","journal-title":"Front Public Health"},{"issue":"6","key":"1541_CR3","doi-asserted-by":"publisher","first-page":"721","DOI":"10.1007\/s40265-024-02039-y","volume":"84","author":"YY Syed","year":"2024","unstructured":"Syed YY. Ensitrelvir fumaric acid: first approval. Drugs. 2024;84(6):721\u20138.","journal-title":"Drugs"},{"issue":"2","key":"1541_CR4","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2023.54991","volume":"7","author":"H Yotsuyanagi","year":"2024","unstructured":"Yotsuyanagi H, Ohmagari N, Doi Y, Yamato M, Bac NH, Cha BK, et al. Efficacy and safety of 5-day oral ensitrelvir for patients with mild to moderate COVID-19: the SCORPIO-SR randomized clinical trial. JAMA Netw Open. 2024;7(2):e2354991.","journal-title":"JAMA Netw Open"},{"issue":"6","key":"1541_CR5","doi-asserted-by":"publisher","first-page":"1287","DOI":"10.1007\/s40121-025-01156-9","volume":"14","author":"M Yamato","year":"2025","unstructured":"Yamato M, Kinoshita M, Yoshida Y, Yamamoto Y, Izuhara R, Sonoyama T. Ensitrelvir in hospitalized patients with SARS-CoV-2 during the omicron epidemic: a single-center observational study. Infect Dis Ther. 2025;14(6):1287\u201397.","journal-title":"Infect Dis Ther"},{"issue":"3","key":"1541_CR6","doi-asserted-by":"publisher","DOI":"10.1016\/j.jiac.2024.12.003","volume":"31","author":"N Hayashi","year":"2025","unstructured":"Hayashi N, Tsukimura E, Ogura E. Ensitrelvir for the treatment of COVID-19: final analysis of a post-marketing surveillance from Japan. J Infect Chemother. 2025;31(3):102574.","journal-title":"J Infect Chemother"},{"issue":"4","key":"1541_CR7","doi-asserted-by":"publisher","DOI":"10.1016\/j.jiac.2025.102669","volume":"31","author":"M Katsuta","year":"2025","unstructured":"Katsuta M, Kitazono M, Nagai N, Karibe H, Takahashi Y, Ariwa Y, et al. The time to return-to-work in healthcare workers with COVID-19 treated with ensitrelvir, a novel oral inhibitor of 3C-like protease of SARS-CoV-2: an observational study utilizing pre-existing data from a single hospital. J Infect Chemother. 2025;31(4):102669.","journal-title":"J Infect Chemother"},{"issue":"5","key":"1541_CR8","doi-asserted-by":"publisher","DOI":"10.1128\/spectrum.03407-24","volume":"13","author":"N Miyashita","year":"2025","unstructured":"Miyashita N, Horita N, Nakamori Y, Ogata M, Fukuda N, Yamura A, et al. Effectiveness of ensitrelvir for cough caused by COVID-19 Omicron variant in patients with asthma. Microbiol Spectr. 2025;13(5):e0340724.","journal-title":"Microbiol Spectr."},{"issue":"10","key":"1541_CR9","doi-asserted-by":"publisher","DOI":"10.1128\/aac.00632-22","volume":"66","author":"R Shimizu","year":"2022","unstructured":"Shimizu R, Sonoyama T, Fukuhara T, Kuwata A, Matsuo Y, Kubota R. Safety, tolerability, and pharmacokinetics of the novel antiviral agent ensitrelvir fumaric acid, a SARS-CoV-2 3CL protease inhibitor, in healthy adults. Antimicrob Agents Chemother. 2022;66(10):e0063222.","journal-title":"Antimicrob Agents Chemother"},{"key":"1541_CR10","unstructured":"Horiuchi K, Koshimichi H, Matsuzaki T, Shimizu R, Kubota R, Sakamoto S. Prediction of drug\u2013drug interaction of ensitrelvir as CYP3A substrate using physiologically-based pharmacokinetic model. In: Poster presented at: 25th North American ISSX meeting (September 10\u201313, 2023; Boston, MA, USA)."},{"issue":"5","key":"1541_CR11","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1007\/s40261-023-01265-8","volume":"43","author":"R Shimizu","year":"2023","unstructured":"Shimizu R, Sonoyama T, Fukuhara T, Kuwata A, Matsuzaki T, Matsuo Y, et al. Evaluation of the drug\u2013drug interaction potential of ensitrelvir fumaric acid with cytochrome P450 3A substrates in healthy Japanese adults. Clin Drug Investig. 2023;43(5):335\u201346.","journal-title":"Clin Drug Investig"},{"issue":"8","key":"1541_CR12","doi-asserted-by":"publisher","first-page":"918","DOI":"10.1002\/jcph.2247","volume":"63","author":"R Shimizu","year":"2023","unstructured":"Shimizu R, Matsuzaki T, Oka R, Sonoyama T, Fukuhara T, Kuwata A, et al. Evaluation of drug\u2013drug interactions of ensitrelvir, a SARS-CoV-2 3CL protease inhibitor, with transporter substrates based on in vitro and clinical studies. J Clin Pharmacol. 2023;63(8):918\u201327.","journal-title":"J Clin Pharmacol"},{"key":"1541_CR13","unstructured":"U.S. Food and Drug Administration. Clinical drug interaction studies with combined oral contraceptives: guidance for industry (June 2023). https:\/\/www.fda.gov\/media\/143849\/download. Accessed 18 July 2025."},{"issue":"6","key":"1541_CR14","doi-asserted-by":"publisher","first-page":"718","DOI":"10.1124\/dmd.122.000854","volume":"51","author":"L Li","year":"2023","unstructured":"Li L, Yang X, Tran D, Seo SK, Lu Y. Combined oral contraceptives as victims of drug interactions. Drug Metab Dispos. 2023;51(6):718\u201332.","journal-title":"Drug Metab Dispos"},{"key":"1541_CR15","unstructured":"U.S. Food and Drug Administration. YAZ (drospirenone\/ethinyl estradiol tablets), for oral use, Highlights of prescribing information (Revised May 2023). https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2023\/021676s020lbl.pdf. Accessed 19 Sept 2025."},{"key":"1541_CR16","unstructured":"U.S. Food and Drug Administration. PAXLOVID\u2122 (nirmatrelvir tablets; ritonavir tablets), co-packaged for oral use, highlights of prescribing information (Revised February 2025). https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2025\/217188s010lbl.pdf. Accessed 18 July 2025."},{"issue":"8","key":"1541_CR17","doi-asserted-by":"publisher","first-page":"1403","DOI":"10.1093\/cid\/ciac933","volume":"76","author":"H Mukae","year":"2023","unstructured":"Mukae H, Yotsuyanagi H, Ohmagari N, Doi Y, Sakaguchi H, Sonoyama T, et al. Efficacy and safety of ensitrelvir in patients with mild-to-moderate coronavirus disease 2019: the phase 2b part of a randomized, placebo-controlled, phase 2\/3 study. Clin Infect Dis. 2023;76(8):1403\u201311.","journal-title":"Clin Infect Dis"},{"issue":"1","key":"1541_CR18","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1016\/j.clinthera.2017.08.021","volume":"40","author":"C Johnson-Agbakwu","year":"2018","unstructured":"Johnson-Agbakwu C, Brown L, Yuan J, Kissling R, Greenblatt DJ. Effects of flibanserin on the pharmacokinetics of a combined ethinylestradiol\/levonorgestrel oral contraceptive in healthy premenopausal women: a randomized crossover study. Clin Ther. 2018;40(1):64\u201373.","journal-title":"Clin Ther"},{"issue":"1","key":"1541_CR19","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1007\/s40120-024-00686-7","volume":"14","author":"ME Rosa","year":"2025","unstructured":"Rosa ME, Juh\u00e1sz Z, P\u00e1sztor M\u00e9sz\u00e1ros G, Magyar G, Hars\u00e1nyi J, Szatm\u00e1ri B, et al. Lack of clinically meaningful effect of cariprazine on the pharmacokinetics of a combined oral contraceptive. Neurol Ther. 2025;14(1):291\u2013301.","journal-title":"Neurol Ther"},{"issue":"6","key":"1541_CR20","doi-asserted-by":"publisher","first-page":"1399","DOI":"10.1111\/bcp.12745","volume":"80","author":"H Wiesinger","year":"2015","unstructured":"Wiesinger H, Berse M, Klein S, Gschwend S, H\u00f6chel J, Zollmann FS, et al. Pharmacokinetic interaction between the CYP3A4 inhibitor ketoconazole and the hormone drospirenone in combination with ethinylestradiol or estradiol. Br J Clin Pharmacol. 2015;80(6):1399\u2013410.","journal-title":"Br J Clin Pharmacol"},{"issue":"4","key":"1541_CR21","doi-asserted-by":"publisher","first-page":"798","DOI":"10.1002\/cpt.1848","volume":"108","author":"H Wiesinger","year":"2020","unstructured":"Wiesinger H, Klein S, Rottmann A, Nowotny B, Riecke K, Gashaw I, et al. The effects of weak and strong CYP3A induction by rifampicin on the pharmacokinetics of five progestins and ethinylestradiol compared to midazolam. Clin Pharmacol Ther. 2020;108(4):798\u2013807.","journal-title":"Clin Pharmacol Ther"},{"issue":"4","key":"1541_CR22","doi-asserted-by":"publisher","first-page":"901","DOI":"10.1002\/cpt.2689","volume":"112","author":"E Helmer","year":"2022","unstructured":"Helmer E, Karimian N, Van Assche K, Seghers I, Le Tallec S, Cherala G, et al. Ziritaxestat drug\u2013drug interaction with oral contraceptives: role of SULT1E1 inhibition. Clin Pharmacol Ther. 2022;112(4):901\u20138.","journal-title":"Clin Pharmacol Ther"},{"key":"1541_CR23","unstructured":"U.S. Food and Drug Administration. Fact sheet for healthcare providers: emergency use authorization for LAGEVRIO\u2122 (molnupiravir) capsules. https:\/\/www.fda.gov\/media\/155054\/download. Accessed 18 July 2025."}],"container-title":["Clinical Drug Investigation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40261-026-01541-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40261-026-01541-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40261-026-01541-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,22]],"date-time":"2026-04-22T13:39:49Z","timestamp":1776865189000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40261-026-01541-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,31]]},"references-count":23,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,5]]}},"alternative-id":["1541"],"URL":"https:\/\/doi.org\/10.1007\/s40261-026-01541-3","relation":{},"ISSN":["1173-2563","1179-1918"],"issn-type":[{"value":"1173-2563","type":"print"},{"value":"1179-1918","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,31]]},"assertion":[{"value":"14 November 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 March 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 March 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All authors are full-time employees of Shionogi & Co., Ltd.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"The datasets generated and\/or analyzed during the current study are available from the corresponding author upon reasonable request.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of Data and Material"}},{"value":"This study was conducted in accordance with the Declaration of Helsinki, the Council for International Organizations of Medical Sciences (CIOMS) International Ethical Guidelines, the Good Clinical Practice (GCP) Guidelines set forth by the International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH), and other applicable laws and regulations. The protocol and other relevant documents were reviewed and approved by the institutional review board (IRB) of the study site. The study was approved by the Advarra IRB (approval date: 06 Dec 2024): 6100 Merriweather Dr., Suite 600, Columbia, MD 21044 (Phone: 877-992-4724).","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Approval"}},{"value":"Informed consent was obtained from all individual participants included in the study.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to Participate"}},{"value":"Consent to publish was obtained using the informed consent form for the use of anonymized data for any summary results, reports, or publications produced at the end of the study.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to Publish"}},{"value":"Not applicable.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code Availability"}},{"value":"RS contributed to the conception or design of the study, data interpretation, and drafting of the initial version of the manuscript. RYS and RK contributed to the conception or design of the study and data interpretation. SO contributed to the conception or design of the study, data acquisition and analysis, and data interpretation. TS contributed to data interpretation. All authors contributed to the critical revision of the manuscript for important intellectual content, agreed to be accountable for all aspects of the work, and have read and approved the final version of the manuscript.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Authors\u2019 Contributions"}}]}}